Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03609398 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine
A Phase 2 study of Rift Valley Fever, sponsored by U.S. Army Medical Research and Development Command.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT03609398 is a Phase 2 study of Rift Valley Fever that is actively recruiting participants, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 500 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03609398, a Phase 2 study of Rift Valley Fever, is actively recruiting participants, sponsored by U.S. Army Medical Research and Development Command.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to collect safety and immunogenicity data for an Rift Valley Fever (RVF) vaccine
Conditions Studied
Interventions
- BIOLOGICAL RVF Vaccine
Study Locations (1)
Maryland
- Special Immunization Program, Division of Medicine, USAMRIID - Fort Deterick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2018-10-04 |
| Est. Completion | 2024-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03609398
The ClinicalTrials.gov registry entry for NCT03609398 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rift Valley Fever appearing as the primary indexed condition, and to 1 intervention - of which RVF Vaccine is the first listed.
NCT03609398 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03609398 about?
NCT03609398 is a clinical study titled "Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine". This study is to collect safety and immunogenicity data for an Rift Valley Fever (RVF) vaccine
What is the current status of trial NCT03609398?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2018-10-04. Estimated completion is 2024-12.
What conditions does trial NCT03609398 study?
This clinical trial studies the following conditions: Rift Valley Fever.
What interventions are being tested in trial NCT03609398?
The interventions under investigation include: RVF Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03609398?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03609398 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rift Valley Fever
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.